Drug Profile

Research programme: cardiovascular therapeutics - Cynata Therapeutics

Latest Information Update: 17 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cynata Therapeutics
Developer Cynata Therapeutics; St Vincent Institute of Medical Research; University of New South Wales; University of Sydney
Class Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Feb 2026 Preclinical trials in Ischaemic heart disorders in Australia (Parenteral), before February 2026 (Cynata Therapeutics pipeline, February 2026)
16 Feb 2026 Pharmacodynamics data from a preclinical trial in Ischemic heart disorders released by Cynata Therapeutics (Cynata Therapeutics pipeline, February 2026)
16 Feb 2026 Pharmacodynamics data from a preclinical trial in Myocardial infarction released by Cynata Therapeutics (Cynata Therapeutics pipeline, February 2026)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com